Tolmetin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tolmetin: From NSAID Use to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Tolmetin is a non-steroidal anti-inflammatory drug (NSAID), historically used for rheumatoid arthritis, osteoarthritis, and juvenile rheumatoid arthritis. The TxGNN model’s top-ranked prediction is Acromesomelic dysplasia, Hunter-Thompson type, but this is supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic assessment flags this as a likely knowledge-graph embedding artifact rather than a genuine pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in India regulatory data; internationally known for rheumatoid arthritis, osteoarthritis, and juvenile rheumatoid arthritis (NSAID class) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for Tolmetin is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, Tolmetin is an NSAID that inhibits COX-1/COX-2 enzymes, reducing prostaglandin synthesis to produce anti-inflammatory and analgesic effects.
The top-ranked TxGNN prediction, however, does not have a plausible mechanistic link to this MOA. Acromesomelic dysplasia, Hunter-Thompson type is a rare monogenic skeletal dysplasia caused by GDF5 mutations, with no established inflammatory or COX-pathway pathology. The evidence pack’s own rationale explicitly states this is “極可能為知識圖譜嵌入雜訊（embedding artifact）” — most likely graph-embedding noise rather than a real pharmacological signal. The same caveat applies to ranks 2–6, 8, 9, and 10 in this candidate set, all of which are rare genetic/developmental syndromes without inflammatory pathology.
Among the ten predictions reviewed, only rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (rank 7, score 99.75%) shows a mechanistically coherent link: Tolmetin’s COX inhibition is consistent with its historical clinical use in juvenile rheumatoid arthritis. This candidate reached Evidence Level L4 / Decision Stage S1 (“Research Question”), notably higher than the top-ranked candidate, though it still lacks direct trial or literature support in this dataset.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Tolmetin is currently not marketed in India (0 registrations); no license or approved-indication records are available in this evidence pack.
Safety Considerations
- Drug Interactions: 153 total interactions identified (DDInter). Notable Moderate-level interactions include:
- Corticosteroids (Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide) — combined use with NSAIDs may increase GI bleeding/ulceration risk
- Other NSAIDs/analgesics (Acetylsalicylic acid)
- Antidiabetic agents (Metformin, Chlorpropamide, Glimepiride)
- Aminosalicylates (Mesalazine, Balsalazide)
- Potassium supplements (Potassium citrate, Potassium bicarbonate)
- Naltrexone
Minor-level interactions include H2-antagonists (Famotidine, Ranitidine, Cimetidine) and Linaclotide.
Detailed key warnings and contraindications (TFDA/India label) are not yet available — this is flagged as a Blocking data gap (DG001) and must be resolved before any safety-stage review.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction has a very high TxGNN score but no supporting clinical or literature evidence, and its own mechanistic assessment identifies it as likely model noise rather than a genuine signal. Combined with the absence of India market presence, MOA data, and label safety data (Blocking data gap DG001), this candidate does not meet the bar to advance.
To proceed, the following is needed:
- India/TFDA label warnings and contraindications (DG001, Blocking) — required before any S1 safety review
- Confirmed mechanism of action data (DG002, High) — required to validate or rule out mechanistic plausibility
- Independent validation of the rank-1 prediction (e.g., re-run with alternative embedding/model) given the self-flagged noise concern
- If pursuing an alternative direction: clinical trial and literature search specifically for Tolmetin in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (rank 7), which currently has the strongest mechanistic rationale in this candidate set despite lacking direct evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.